ADVANCIS

Antimicrobial Stewardship

A Global Emergency



- ✓ Antimicrobial resistance is a global emergency
- ✓ Easier exudate management
- ✓ Superior handling

www.advancismedical.com

What is Antimicrobial Stewardship?

“a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials.” (WHO, 2021).




Antimicrobial Resistance is

the ability of a microorganism to survive and resist exposure to antimicrobial drugs, threatening the effectiveness of successful treatment of infection

Why Does Antimicrobial Stewardship Matter?

"Antimicrobial resistance (AMR) is a global public health emergency. AMR is the ability of a microorganism to survive and resist exposure to antimicrobial drugs, threatening the effectiveness of successful treatment of infection."

(WHO 2021)



1. Between 2019-2050 could see an increase of 68% in deaths associated with Antimicrobial Resistance. [1]
2. If we don't improve priority treatments like surgery and wound care, it will carry a higher risk.
3. The development of new antibiotics is declining, while resistance to antibiotics is rising. [2]

Comparison of Antibacterial Topical Agents

	Advancis Medical Grade Manuka Honey	Silver (Ag)	Iodine (I)	DACC (Dialkylcarbamoyl Chloride)	PHMB (polyhexamethylene biguanide)
Effective antibacterial activity time	7 days [a]	Varies, limited use of 4 weeks [d]	2 days maximum [f]	18-24 hours [k]	4 days [m]
Any known bacterial resistance	No [b]	Yes [e]	No [g]	No [l]	No [n]
Suitable for debridement	✔		No	No	✔ [o]
Promotes granulation	✔		✔ [h]	✔ [l]	✔ [p]
Reduces odour	✔ [c]	✔ [c]	✔ [c]		✔ [p]
Limitations of Use	Honey and bee venom allergy	Potentially cytotoxic [d]	Contra-indications for kidney [i]	Must be in contact with the bacterial cells to remove	
Limited treatment time	No	✔	✔ [j]	No [l]	No
Natural substance	✔	✔	✔	No	No

Reducing Antimicrobial Resistance (AMR)

An estimated 4.95 million deaths associated with bacterial AMR in 2019. This includes 1.27 million deaths attributable to bacterial AMR. With a forecast of 8.22 million deaths associated with AMR in 2050, globally.[q]

With AMR growing, there has been a search for new antibiotics and alternative treatments, such as medical grade Manuka honey. With importance being placed on having a multidisciplinary approach, both biological and social sciences, to effectively anage and reduce AMR. [r]



References

a. Test data on file.

b. Seckam, A. and Cooper, R. (2013) Understanding how honey impacts on wounds: an update on recent research findings, *Wounds International*, 4(1). pp 20-24.

c. Akhmetova, A., Saliev, T., Allan, I.U. et al. (2016) A Comprehensive Review of Topical Odor-Controlling Treatment Options for Chronic Wounds. *J Wound Ostomy Continence Nurs.* 43(6): pp 598-609.

d. International consensus. Appropriate use of silver dressings in wounds. An expert working group consensus. London: *Wounds International*, 2012. Available to download from: www.woundsinternational.com

e. Rippon, M. and Rogers, A. (2025) Development of silver resistance: a focus on wound care, *Wounds International*, 16(2). pp 20-37.

f. NHS Grampian Joint Wound Care Formulary (2015) Available at: https://www.nhsgrampian.org/globalassets/foidocument/foi-public-documents1---all-documents/WCF_Inadine.pdf?UNLID=51000024120264302317 34 (Accessed: 20 May 2026).

g. Lepelletier, D., Maillard, J.Y., Pozzetto, B. et al. (2020) Povidone Iodine: Properties, Mechanisms of Action, and Role in Infection Control and Staphylococcus aureus Decolonization, *Antimicrobial Agents and Chemotherapy*, 64(9). pp 1-13.

h. Hasniatisari, H., Susilo, H., Mirwanti, R. et al. (2024) Uncovering the Benefits of Povidone Iodine Compared to Other Therapeutic Agents in Wound Infection Prevention and Healing Outcomes: A Scoping Review, *Journal of Multidisciplinary Healthcare*, 2024(17). pp 3605-3616

i. CHFT News (2024) *Inadine products have been upgraded to contraindications*. Available at: https://chft-news.cht.nhs.uk/issue/chft-news-issue-71-10-june-2024/article/inadine-products-have-been-upgraded-to-contraindications-80b3b55dc14c (Accessed: 15 June 2026).

j. British National Formulary (BNF) (no date) *Iodine dressings*. Available at: https://bnf.nice.org.uk/wound-management/antimicrobial-dressings/iodine-dressings/ (Accessed: 15 June 2026).

k. Husmark, J., Morgner, B., Susilo, Y.B., et al. (2022) Journal of Wound Care (2022) *Antimicrobial effects of bacterial binding to a dialkylcarbamoyl chloride-coated wound dressing: an in vitro study*, 31(7). pp 560 - 570

l. Edwards-Jones V, Idensohn T, Westgate S et al (2025) Dialkylcarbamoyl Chloride-coated wound dressings: An evidence review and position document. Wounds International

m. Moore, K. and Gray, D. (2007) Using PHMB antimicrobial to prevent wound infection, Wounds UK, 3(2). pp 96-102.

n. Chindera, K., Mahato, M., Sharma, A.K., et al. (2016) The antimicrobial polymer PHMB enters cells and selectively condenses bacterial chromosomes, *Scientific Reports*, 6(23121).

o. Mancini, S., Cuomo, R., Poggialini, M. et al (2017) Autolytic debridement and management of bacterial load with an occlusive hydroactive deressing impregnated with polyhexamethylene biguanide, *Acta Biomed*, 88(4). pp 409-413

p. Eberlein, T. (2014) 'Use of a cellulose PHMB dressing in clinical practice', *Wounds UK*, 26th February. Available at: https://wounds-uk.com/case-studies/use-cellulose-phmb-dressing-clinical-practice/ (Accessed: 16 June 2026).

q. Naghavi, M., Vollset, S., Ikuta, K. et al. (2024) Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050, *The Lancet*, 404(10459). pp 1199-1226.

r. Calvo-Villamañán, A., San Millán, Á. and Carrilero, L. (2023) Tackling AMR from a multidisciplinary perspective: a primer from education and psychology. *Int Microbiol*, 26, pp 1-9.

Methicillin-Resistant Staphyloc occus Aureus (MRSA) Pathway

Develops clinical signs/symptoms of infection and/or patient has history of MRSA with new ulceration present?

Yes - Follow the below pathway

No - Follow local policies and guidelines

Take and send a wound swab or tissue sample to microbiology for culture and sensitivity, or follow your local policies and guidelines.

Assess results for antibiotic sensitivities and resistances.

If MRSA bacterial growth is present, report to the Infection Prevention team and/or a relevant medical specialist.

Update patient, family and/or carer on findings and document in patient's records, including any domestic team involved in patient care.

Following medical advice: start decolonisation process.

1. Antibiotic therapy for 14 days with sensitive antibiotic.
2. Use an antibacterial skin cleanser (i.e. 4% Chlorhexidine Gluconate).
3. Mupirocin nasal spray 3 times daily for 5 days.
4. Use a relevant antimicrobial wound irrigation solution to aid wound decolonisation at each wound review.

Schedule patients with MRSA last to reduce bacterial spread.

Ensure good hand hygiene practices are followed, Aseptic Non-Touch Technique (ANTT) used during treatment and Personal Protective Equipment (PPE) worn throughout patient contact.

When reviewing, follow your local policies and guidelines while reassessing for antibiotic optimisation within a clinically relevant time period.

This pathway was created in conjunction with Laura Seddon, Clinical Lead Podiatrist- High Risk Foot Team at Stockport NHS Foundation Trust | Division of Integrated Care

Should we be doing more to prevent wound infections

and the subsequent requirement for antibiotic prescriptions?



Interpreting UK NHS Data

These graphs reference the publication “Cohort study evaluating the burden of wounds to the UK’s National Health Service in 2017/2018: update from 2012/2013”, a representative sample of 3,000 patients, randomly selected from a cohort of 174,569 patients with a wound related wound read code by IQVIA in 2017 to 2018.[5]

Figure 1

shows the measured infection rate of different types of wound. It can be noted that the rate of infection on the type of wounds treated in community, particularly relating to diabetic foot ulcers and venous leg ulcers is disproportionally high.




Figure 1: Percentage of all wounds with a recorded infection (1 March 2017 - 28 February 2018)

Figure 2

shows the amount of patients with infections who were subsequently prescribed antibiotics and Figure 3 shows the amount of patients who were admitted to hospital for the treatment of an infection.





Figure 2: Patients who were prescribed antibiotics in the study year

Figure 3

shows the numbers of patients that were prescribed antibiotics in the study year.

Figure 3: Hospital admissions appearing to be linked to a suspected infection



There is an argument that we should be doing more to prevent infections and the subsequent antibiotic prescriptions that contribute to antimicrobial resistance. This would also reduce clinical time and costs associated with resultant hospital admissions for treatment.

This could be achieved through better education on the subject of infections and antimicrobial resistance and informed practices, or via the prophylactic use and antibacterials to help prevent infections.

Education Hub

Visit the Advancis Education Hub

A dedicated space for healthcare professionals:

- Wound care fundamentals courses
- Continuing Professional Development (CPD) courses
- Wound care application and product usage tips with Tissue Viability Nurses
- Wound and product selection guides
- Wound care research and clinical updates
- Advancis product case studies and clinical evaluations

www.advancismedical.com/education



Ordering Codes

Product	REF	Size	Pack Size	PIP Code	NHS SC Code
Actilite	CR4281 CR3849 CR3852 CR4366 CR4367 CR4368	5cm x 5cm 10cm x 10cm 10cm x 20cm 20cm x 30cm 30cm x 30cm 30cm x 40cm	10 10 10 10 5 5	379-3759 335-4917 335-4925 398-8078 398-8086 398-8094	EJE079 EJE042 EJE040 EJE163 EJE164 ELY869
Activon Manuka Honey Barrier Cream	CR4546	100g	1	435-4411	ELZ85134
Activon Tube	CR4493	20g	12	419-7646	ELY864
Activon Tulle	CR3761 CR3658	5cm x 5cm 10cm x 10cm	5 5	304-0631 304-0623	EJE027 EJE028
Algivon	CR383 1 CR3659	5cm x 5cm 10cm x 10cm	10 10	319-3711 319-3703	ELS846 ELS195
Algivon Plus	CR4230 CR422 5	5cm x 5cm 10cm x 10cm	5 5	374-9496 374-9512	ELS549 ELS550
Algivon Plus Ribbon *(with wound probe)*	CR423 1	2.5cm x 20cm	5	374-4653	ELS551







MAR877/V1

Get in touch

+44 (0)1623 751 500

info@advancis.co.uk

Find us online

www.advancismedical.com

References

1. World Health Organization (2022). WHO antimicrobial stewardship toolkit.
2. National Biofilms Innovation Centre. Understanding biofilms.
3. Cooper RA, Jenkins L, Henriques AFM, Duggan RS, Burton NF (2010) Absence of bacterial resistance to medical grade manuka honey. Eur J Clin Microbial Infect Dis 29: 1237-41.
4. Percival SL et al. Development of silver resistance: A focus on wound care.
5. Guest JF, Fuller GW, Vowden PCohort study evaluating the burden of wounds to the UK's National Health Service in 2017/2018: update from 2012/2013BMJ Open 2020;10:e045253. doi: 10.1136/bmjopen-2020-045253.
6. Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet 2022;399:629–55.

Actilite, Activon and Algivon are trademarks of Brightwake Ltd. Contact info@advancis.co.uk for more information.